Radka Graf

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index1.1kcitations20works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(8), Neurotransmitter Receptor Influence on Behavior(4), Neuroscience and Neuropharmacology Research(4), Phosphodiesterase function and regulation(3), Autism Spectrum Disorder Research(2)

Publications20 total

Reproducibility via coordinated standardization: a multi-center study in a Shank2 genetic rat model for Autism Spectrum Disorders
Scientific Reports·2019· 32 citedOpen Access
Characterization of GI Barrier Integrity and Gut Microbiome-Derived Metabolites in BTBR, Shank3 and Cntnap2 Mouse Models of ASD, and Demonstration of AB-2004 As a Potential Mitigating Therapeutic
INSAR 2019 Annual Meeting·2019· 1 cited
P.2.13 High reproducibility across sites in a pre-clinical study through a coordinated behavioural and pharmacological protocol
European Neuropsychopharmacology·2019· 1 citedOpen Access
Hyperactivity and Hypermotivation Associated With Increased Striatal mGluR1 Signaling in a Shank2 Rat Model of Autism
Frontiers in Molecular Neuroscience·2018· 35 citedOpen Access
The location discrimination reversal task in mice is sensitive to deficits in performance caused by aging, pharmacological and other challenges
Journal of Psychopharmacology·2018· 10 cited
An investigation of metabotropic glutamate receptor 5 negative allosteric modulators in physiological and behavioral indicators of anxiety and cognition in rodents
The FASEB Journal·2013
Novel triazines as potent and selective phosphodiesterase 10A inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 26 citedOpen Access
In-Vivo Detection of Late Persistent Microglia Activation in the Chronic Phase of Embolic Stoke in Rats (PD2.002)
Neurology·2012
Highly Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitors
Journal of Medicinal Chemistry·2011· 72 citedOpen Access
5-Cyclic Amine-3-arylsulfonylindazoles as Novel 5-HT<sub>6</sub> Receptor Antagonists
Journal of Medicinal Chemistry·2010· 22 citedOpen Access
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity
Journal of Pharmacology and Experimental Therapeutics·2009· 14 cited
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: A possible therapeutic target for psychiatric disorders?
Molecular and Cellular Neuroscience·2009· 94 cited
Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
Bioorganic & Medicinal Chemistry Letters·2009· 18 citedOpen Access
Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2009· 266 cited
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
Neuropharmacology·2009· 145 cited
Detection of auditory evoked potentials and mismatch negativity-like responses in the awake and unrestrained rat.
UCL Discovery (University College London)·2009· 1 cited
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
Psychopharmacology·2008· 23 cited
ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities
Journal of Pharmacology and Experimental Therapeutics·2008· 181 cited
PRE-CLINICAL CHARACTERIZATION OF THE ALPHA-7 NICOTINIC RECEPTOR AGONIST SEN12333/WAY-317538
Schizophrenia Research·2008
Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test
Progress in Neuro-Psychopharmacology and Biological Psychiatry·2007· 181 cited

Frequent Co-authors

Karen L. Marquis(9), Rachel L. Navarra(8), Steven M. Grauer(7), Sheree F. Logue(6), Zoë A. Hughes(6), Julie Brennan(5), Thomas A. Comery(5), Nicholas J. Brandon(5), Sharon Rosenzweig‐Lipson(5), Albert J. Robichaud(5), Deborah L. Smith(4), Cody Kelley(3), Barbara Langen(3), Ute Egerland(3), Michael S. Malamas(3), Thorsten Hage(3), Steve Grauer(3), Margaret Lai(3), Farhana Pruthi(3), Claudine Pulicicchio(3)